Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-07-21

Clinical Trial Update: Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) [Phase 2]

View source ↗

Summary

Phase 2 study of CEP-701 (lestaurtinib) in patients with acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lestaurtinib (lestaurtinib)

Snippet

Sponsor: Cephalon | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED